CANF
Can-Fite BioPharma Ltd.·Healthcare
3.31
3.878%(−0.13)
Market OpenLast Updated: — ET
52W L: $2.8352W H: $23.40
CANF NEWS
globenewswire.com
May 18
Scientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson’s Potential in the Multi-Billion Dollar Canine Osteoarthritis Market
Ramat Gan, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced publication of a peer-reviewed scientific article regarding previously reported positive findings from a study evaluating Piclidenoson for the treatment of canine osteoarthritis.
globenewswire.com
May 18
Scientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson's Potential in the Multi-Billion Dollar Canine Osteoarthritis Market
Ramat Gan, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced publication of a peer-reviewed scientific article regarding previously reported positive findings from a study evaluating Piclidenoson for the treatment of canine osteoarthritis. The article abstract, titled “ Piclidenoson, an A3 Adenosine Receptor Agonist, Improves Clinical Signs in Dogs with Osteoarthritis ” was published in the peer-reviewed journal Frontiers in Veterinary Science and is available online.
globenewswire.com
May 13
Following Positive Phase 2a Pancreatic Cancer Data, Can-Fite Advances Namodenoson into Phase 2b Combination Study with Immunotherapy
Phase 2b study design to be discussed at BIO International Convention in San Diego as Can-Fite advances partnership negotiations with leading oncology companies Ramat Gan, Israel, May 13, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF; TASE: CANF), a clinical-stage biotechnology company developing oral small molecule drugs targeting the A3 adenosine receptor (A3AR), today announced plans to advance its pancreatic cancer program into a Phase 2b study evaluating Namodenoson in combination with immunotherapy in patients with advanced pancreatic cancer.
globenewswire.com
Apr 30
Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months
Ramat Gan, Israel, April 30, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs for the treatment of cancer and inflammatory diseases, today announced positive clinical data from its Phase 2a study of namodenoson in patients with advanced pancreatic cancer.
globenewswire.com
Mar 30
Can-Fite's Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026
Can-Fite Signed a Deal Worth up to $325M with the Veterinary Company Vetbiolix Ramat Gan, Israel, March 30, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that its veterinary partner Vetbiolix has completed enrollment in a Phase 2 study of Piclidenoson for the treatment of osteoarthritis in dogs.
globenewswire.com
Mar 26
Can-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient
RAMAT GAN, Israel, March 26, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced clinical updates and financial results for the year ended December 31, 2025 and early 2026.
